Elite Pharmaceuticals Files ANDA for Oxycodone Hydrochloride Extended Release
September 20, 2017 08:37 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced that it has filed an Abbreviated New Drug Application (ANDA) with...
NEW REPORT FROM GRANTMAKERS IN AGING EXPLORES IMPACT OF THE OPIOID EPIDEMIC ON RURAL AGING
August 24, 2017 08:00 ET
|
Grantmakers In Aging
Washington, DC, Aug. 24, 2017 (GLOBE NEWSWIRE) -- The opioid crisis is a story of many types of pain, and how individuals, families, and entire communities – particularly small and rural ones – are...
Trevena Attends National Institutes of Health Meeting to Discuss Development of Novel, Improved Pain Medications
June 20, 2017 16:01 ET
|
Trevena Inc.
KING OF PRUSSIA, Pa., June 20, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced its recent participation in the “Cutting Edge Science Meeting Series to End the Opioid Crisis:...
BioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its Drug Development Team, Plans Pre-IND Meeting with FDA
November 28, 2016 06:00 ET
|
BioCorRx
ANAHEIM, CA, Nov. 28, 2016 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTC PINK: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions,...
Issue Brief Explores the Many Facets of Opioid Abuse
September 14, 2016 07:33 ET
|
The Center for Health Affairs
CLEVELAND, Sept. 14, 2016 (GLOBE NEWSWIRE) -- The Center for Health Affairs' August 2016 Issue Brief, A Growing Epidemic: Battling Opioid Abuse in Ohio, explores the many facets of the opioid abuse...
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
October 21, 2015 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced positive top-line results from the Phase 3 pivotal trial of...
BioCorRx, Inc. Announces Start Fresh Program(r) availability at Irvine, CA Wellness Center
August 27, 2015 08:00 ET
|
BioCorRx
Los Angeles, Aug. 27, 2015 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (BICX), developer of the Start Fresh Program, a Medication-Assisted Treatment (MAT) program, announces distribution to Next Advanced...
BioCorRx, Inc. and Sobriety and Addiction Solutions, LLC Announce Mutual Separation; Plan to Advocate for Wider Naltrexone Implant Use in the Treatment of Addiction
July 02, 2015 14:54 ET
|
BioCorRx
Los Angeles, July 2, 2015 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (BICX), developer of the Start Fresh Program, announces the mutual release of Sobriety and Addiction Solutions, LLC (SAS) from its license...
Born an Addict: ARUP Searches for Clues in the Umbilical Cord
April 28, 2015 14:20 ET
|
ARUP Laboratories
SALT LAKE CITY, April 28, 2015 (GLOBE NEWSWIRE) -- Every baby born that enters this world, arrives with an umbilical cord in tow. For those babies born addicted to drugs, that umbilical cord is now a...
Elite Pharmaceuticals Announces Results of 2014 Annual Meeting of Shareholders
May 23, 2014 11:08 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 23, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) today announced the voting results of matters considered during the...